Sentences with phrase «head of the oncology»

To get a sense of what that process is like, at least at one major pharmaceutical company, we turned to Bob Abraham, Pfizer's head of oncology research and development.

Roche has four biologic cancer immunotherapy molecules in clinical trials that could work in powerful combinations with each other or with current drugs, says William Pao, global head of oncology discovery in Basel.

Susan Galbraith, head of the oncology innovative medicines unit at AstraZeneca, said: «Lung cancer is still the leading cancer killer, and we are working on a number of potential treatment options that could provide patients with a better chance of beating the disease.

Dr. Bolen, the chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company has served in senior leadership positions at Millennium since 1999.

Charlotte Niemeyer, M.D. (Professor and Head of Oncology, Univ..

Frank Hsu joined Immune Design in October 2013 as Vice President, Head of Oncology.

«We would like to include everything in our toolbox that is necessary to put together the ideal therapy for a patient», says project coordinator Heike Walles, professor of tissue engineering and regenerative medicine at the University Hospital of Würzburg and also head of the oncology group at the Fraunhofer Institute IGB in Würzburg, Germany.

Dr. Sue Ettinger is a veterinary cancer specialist, international speaker, book author, and is head of the Oncology Department at the Animal Specialty & Emergency Center in NY.

Dr. Sue Ettinger is a practicing veterinary cancer specialist, international speaker, book author, and is currently the head of the Oncology Department at the Animal Specialty & Emergency Center in the Hudson Valley, NY.

Not exact matches

Albert Bourla, head of Pfizer's cancer business, said «immuno - oncology is a top priority for Pfizer.»

He also served as Global Head of the Immuno - Oncology Translational Innovation Platform where he was instrumental in rebuilding immuno - oncology (IO) research at the company, including pruning and re-orienting the discovery pOncology Translational Innovation Platform where he was instrumental in rebuilding immuno - oncology (IO) research at the company, including pruning and re-orienting the discovery poncology (IO) research at the company, including pruning and re-orienting the discovery pipeline.

Professor Josep Tabernero, a member of the scientific committee for the EORTC - NCI - AACR Symposium and head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheoncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheOncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to other drugs.

Commenting on the study for ESMO, Dr Olivier Michielin, head of Personalised Analytical Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, said: «Omaveloxolone's novel mechanism of action is to block MDSCs, cells known to suppress the immune response.

The study, was reported Feb 13 to the 5th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO) will reduce significantly the number of HNSCC patients who currently undergo selective neck dissection (SND), a procedure which involves removing a group of lymph nodes from the neck in order to try to eradicate those which may have been reached by the cancer.

The study of 1,003 men was conducted at the NIH in Bethesda, Md., from 2007 - 2014, with Peter A. Pinto, MD, the head of the prostate cancer section of the urologic oncology branch, serving as the senior investigator.

Dr Gerrit - Jan Liefers (MD, PhD), a surgical oncologist and head of the geriatric oncology research group at Leiden University Medical Centre (Leiden, The Netherlands), said: «For a screening program to be effective, one would expect that the incidence of early stage breast cancer would increase while the incidence of advanced stage cancer would decrease because any cancer would have been detected at an earlier stage.

Commenting on the results, Dr Olivier Michielin, head of Personalised Analytical Oncology, CHUV, Lausanne, Switzerland, said: «This was the first attempt to use checkpoint blockade in the adjuvant setting of melanoma.

Mertelsmann, head of the University of Freiburg's oncology and hematology department, immediately called the inquiry «unfair» and vowed to mount a vigorous defense.

The study published today was done in collaboration with the labs headed by Salvador Aznar Benitah and Angel R. Nebreda, both members of IRB Barcelona's Oncology Programme, and with the labs led by Violeta Serra, at the Vall d'Hebrón Institute of Oncology (VHIO), Aleix Prat, at the Hospital Clínic de Barcelona, and Joan Albanell, at the Hospital del Mar..

«Just because you see the light at the end of the tunnel doesn't mean you are near the end of the tunnel,» says Larry Norton, head of medical oncology at Memorial Sloan - Kettering Cancer Center in New York City.

But I would say equally as important, I had a great clinical mentor in Dr. Howard Scher, who is head of the genitourinary oncology service at Sloan - Kettering.

«Patients with non-small cell lung cancer (NSCLC) should receive front line therapy with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib,» said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy.

Commenting on the study, Dr Andres Poveda, Head of the Gynecological Oncology Clinic at Fundación Instituto Valenciano de Oncología, Valencia, Spain, who was not involved in the research, said the CIRCCa study is the second recent trial to show the benefit of adding an antiangiogenic drug to chemotherapy in cervical cancer.

In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.

«Larynx preservation via chemoradiation is an excellent, organ - preserving option to total laryngectomy for many patients with less advanced larynx cancers,» said Alexander Lin, MD, an assistant professor and chief of Head and Neck Service in the department of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania, the study's senior author.

«NYGC is thrilled to have this work be our first published example of the explosive power of collaborations between deeply invested biologists like those in the Simon lab including Elana Simon, and thoughtful bioinformatics scientists like Nicolas Robine and NYGC team, who worked together so effectively with the tools of genomic sequencing and analysis to discover this new chimeric protein and cancer target,» says Robert Darnell, head of Rockefeller's Laboratory of Molecular Neuro - Oncology, HHMI investigator, and president and scientific director of NYGC.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

These cancer - fighting viruses seem to work in two ways, says Andrew Zloza, head of surgical oncology research at the Rutgers Cancer Institute of New Jersey in New Brunswick.

Commenting on the results, Dr Andrés Poveda, head of the Gynaecological Cancer Clinic, Oncology Foundation Institute Valencia, Spain, said: «This study more than doubles the population of patients who benefit from a PARP inhibitor.»

The study, carried out by CNIO, was led by Manuel Serrano, the director of the Molecular Oncology Programme and head of the Tumoural Suppression Laboratory.

«This study, one of only a few large studies to have follow - up beyond five years, demonstrates that patients who have head and neck cancers and who are being treated with radiation therapy alone have improved local - regional control and no increase in late toxicity when radiation therapy is delivered twice a day in two smaller doses which we call hyperfractionation,» said Jonathan J. Beitler, MD, MBA, FASTRO, lead author of the study and professor of radiation oncology, otolaryngology and hematology / medical oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta.

Tweardy is division head of internal medicine and a professor of infectious diseases and molecular and cellular oncology at MD Anderson.

«We've known for years that how well a patient does is directly related to the amount of tumor that the surgeon removes and the amount that's left behind,» says Michael Birrer, who began working with Belcher when he was head of medical gynecologic oncology at Massachusetts General Hospital.

In 2004, Dr. Gary Steinberg moved his bladder cancer practice from Louis A. Weiss Memorial Hospital to the University of Chicago campus to head our oncology program.

Since 2000 Head of Lymphocyte Activation Unit Division of Immunology, Transplantation and Infectious Diseases Program in Immunology, Bio-Immuno-gene therapy of Cancer, IRCCS Ospedale San Raffaele, Milan, Italy 1998 - 1999 Research Associate Department of Molecular Biology and Functional Genomic, IRCCS Ospedale San Raffaele, Milan, Italy 1993 - 1998 Postdoctoral Associate Department of Microbiology University of Minnesota, Medical School Minneapolis, MN, USA 1991 - 1992 Department of Pharmacology, New York University, New York, USA 1989 - 1991 Department of Biomedical Science and Oncology, Turin, Italy 1988 - 1989 Research Fellow Department of Biomedical Science and Oncology, Turin, Italy 1989 - 1992 Ph.D. student in Molecular Oncology 1986 - 1988 Undergraduate student Department of Biomedical Science and Oncology, Turin, Italy

Commenting on the significance of the research, Dr Pilar Garrido, head of the Thoracic Tumour Section of the Medical Oncology Department at Ramón y Cajal University Hospital, Madrid, Spain, said: «Lung cancer is the most common cancer globally, but debate about the optimal screening strategy is ongoing and current selection criteria are based only on age and pack - years.

Dr. Matushansky joins Hookipa from Daiichi Sankyo, where he was the Global Head of Translational Development for Oncology.

The fellowship is offered in collaboration with the department of head and neck surgery, endocrine neoplasia, diagnostic and interventional radiology, neuroradiology, pathology, medical oncology and clinical genetics cancer.

He is now joining the Regulation of Protein Synthesis in Eukaryotes group, headed by Dr. Fátima Gebauer at CRG, and the Pathology and Molecular Oncology team at VHIR, led by Dr. Matilde Lleonart.

Dr. John Lewis the co-founder of Oisin Oncology and heads its cancer - fighting platform technology development and clinical research.

As a result, five - year survival is less than 7 percent across all stages,» says Lauren Byers, MD, lead investigator on the study and associate professor of Thoracic Head & Neck Medical Oncology.

Intensive treatment combining radiation and chemotherapy can control locally advanced head and neck cancer, improve survival, and in most cases eliminate the need for debilitating surgery, report researchers from the University of Chicago Medical Center and Northwestern University in the April 14, 2000, issue of the Journal of Clinical Oncology.

«Bristol - Myers Squibb is thrilled to be part of an innovative research model where each partner acts with urgency to advance potential new treatments for patients facing deadly cancers,» said Awny Farajallah, M.D., vice president, head of U.S. Medical Oncology at Bristol - Myers Squibb.

Head and Neck Oncology, an open access journal with a closed peer - review system, achieved its first official impact factor on the 2nd of July, 2012.

Current address: Department of Radiation Oncology, Ludwig - Maximilians - Universität München, Munich, Germany; Clinical Cooperation Group «Personalized Radiotherapy of Head and Neck Cancer», Helmholtz Center Munich - German Research Center for Environmental Health (GmbH), Munich, Germany

Dr. Mendez is an Associate Member at Fred Hutchinson Cancer Research Center's Clinical Research Division, Associate Professor in the Department of Otolaryngology / Head and Neck Surgery at the University of Washington School of Medicine, and Co-Director of the Head and Neck Oncology Program and Tissue Bank at UW.

May 29, 2015 Pembrolizumab shows real promise against head and neck cancer Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology (ASCO).

The patient in the Annals of Oncology report, «Mr. S» (the authors don't use his name because of confidentiality concerns), had been treated for advanced head and neck cancer.

We are excited to have her join our surgical team where she will continue to offer her skills in the areas of neurosurgery, surgical oncology, limited orthopedic and endoscopic procedures, and all areas of soft tissue surgery including abdominal, gastrointestinal, thoracic, head and neck, reconstructive and urogenital.

After completing a small animal medicine and surgery internship in the New Jersey, she headed back south to the University of Tennessee where she completed her residency in medical oncology.